{
    "2018-09-10": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Most Analysts Currently Call Boston Scientific a ‘Buy’",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Boston Scientific",
                        "Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst Blog",
                        "Abbott",
                        "Gilead",
                        "FedEx",
                        "Archer Daniels",
                        "CBRE"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech",
                        "logistics",
                        "agriculture",
                        "real estate"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-17",
                "original_text": "Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake",
                "features": {
                    "keywords": [
                        "Abbott",
                        "DRG Therapy",
                        "Aetna",
                        "Boost Uptake"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-18",
                "original_text": "Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake",
                "features": {
                    "keywords": [
                        "Abbott",
                        "DRG Therapy",
                        "Aetna",
                        "Boost Uptake"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}